PMID- 29481624
OWN - NLM
STAT- MEDLINE
DCOM- 20190514
LR  - 20190514
IS  - 1569-9285 (Electronic)
IS  - 1569-9285 (Linking)
VI  - 27
IP  - 1
DP  - 2018 Jul 1
TI  - Long-term outcomes using the stentless LivaNova-Sorin Pericarbon Freedom valve 
      after aortic valve replacement.
PG  - 116-123
LID - 10.1093/icvts/ivy012 [doi]
AB  - OBJECTIVES: Information on the long-term safety, efficacy and durability of 
      third-generation stentless aortic valves is lacking. METHODS: In this 
      single-centre, single-surgeon retrospective observational study, between 2003 and 
      2015, consecutive, non-selected aortic valve replacement (AVR) patients were 
      implanted with the LivaNova-Sorin Pericarbon Freedom, a third-generation 
      stentless aortic xenograft. Changes in clinical and echocardiographic parameters 
      were examined, as were mortality, structural valve deterioration and reoperation, 
      according to age at 5, 10 and 14 years. RESULTS: The mean logistic EuroSCORE was 
      8.5% in 22 AVR patients (mean age 68.3 years; range 15-89 years). Many patients 
      [n = 139 (43%)] underwent a concomitant procedure. Before AVR, 68.0% of patients 
      were in New York Heart Association (NYHA) Class I or II, and at discharge, mean 
      gradient was 10.0 +/- 4.3 mmHg. Follow-up lasted up to 8.9 +/- 2.8 years. At the last 
      follow-up, 95.6% of patients were in New York Heart Association Class I or II, 
      the mean gradient was 8.0 +/- 3.5 mmHg (P < 0.001) and reduction in 
      interventricular septum thickness and improvement of ejection fraction were 
      significant (both P < 0.001). Early 30-day in-hospital mortality was 1.6% overall 
      and 0% in the AVR-only population. Overall survival probability was 99.9%, 87.9% 
      and 82.7% at 5, 10 and 14 years. Freedom from structural valve deterioration at 
      14 years was 67.5%, 88.9% and 68.2% in AVR patients overall, in those aged 
      >70 years and in those aged 60-70 years, respectively. Freedom from reoperation 
      at 14 years was 70.3%, 88.3% and 78.0% in the corresponding groups. CONCLUSIONS: 
      Sorin Pericarbon Freedom is a valuable aortic bioprosthesis with favourable 
      haemodynamics, particularly in smaller annuli, and durability similar to that of 
      stented valves, which make Sorin Pericarbon Freedom a useful option in AVR.
FAU - Stefanelli, Guglielmo
AU  - Stefanelli G
AD  - Department of Cardiac Surgery, Hesperia Hospital, Modena, Italy.
FAU - Pirro, Fabrizio
AU  - Pirro F
AD  - Department of Cardiac Surgery, Hesperia Hospital, Modena, Italy.
FAU - Olaru, Alina
AU  - Olaru A
AD  - Department of Cardiac Surgery, Hesperia Hospital, Modena, Italy.
FAU - Danniballe, Giuseppe
AU  - Danniballe G
AD  - Department of Cardiac Surgery, Hesperia Hospital, Modena, Italy.
FAU - Labia, Clorinda
AU  - Labia C
AD  - Department of Cardiac Surgery, Hesperia Hospital, Modena, Italy.
FAU - Weltert, Luca
AU  - Weltert L
AD  - Department of Cardiac Surgery, European Hospital, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - Interact Cardiovasc Thorac Surg
JT  - Interactive cardiovascular and thoracic surgery
JID - 101158399
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aortic Valve Insufficiency/*surgery
MH  - Aortic Valve Stenosis/*surgery
MH  - *Bioprosthesis
MH  - Echocardiography
MH  - Female
MH  - *Heart Valve Prosthesis
MH  - *Heart Valve Prosthesis Implantation
MH  - Hemodynamics
MH  - Hospital Mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prosthesis Design
MH  - Reoperation
MH  - Retrospective Studies
MH  - Stents
MH  - Young Adult
EDAT- 2018/02/27 06:00
MHDA- 2019/05/15 06:00
CRDT- 2018/02/27 06:00
PHST- 2017/09/25 00:00 [received]
PHST- 2018/01/07 00:00 [accepted]
PHST- 2018/02/27 06:00 [pubmed]
PHST- 2019/05/15 06:00 [medline]
PHST- 2018/02/27 06:00 [entrez]
AID - 4898146 [pii]
AID - 10.1093/icvts/ivy012 [doi]
PST - ppublish
SO  - Interact Cardiovasc Thorac Surg. 2018 Jul 1;27(1):116-123. doi: 
      10.1093/icvts/ivy012.